Physician profile
Pavan Devulapally
NPI 1306085477
$3,464.78
in general payments reported to CMS, 2019-2025
22 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $244 · 2021: $321 · 2022: $480 · 2023: $324 · 2024: $479 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.29 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $720.34 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $266.08 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $266.01 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $238.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $207.69 | 2020-2025 | Farxiga |
| Amgen INC. | $157.65 | 2025 | Krystexxa, Tavneos |
| Inari Medical, INC. | $145.71 | 2022 | |
| Mallinckrodt Hospital Products INC. | $144.48 | 2021-2023 | Acthar |
| Horizon Therapeutics Plc | $143.64 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $136.86 | 2019 | |
| Bard Peripheral Vascular, INC. | $127.95 | 2020 | |
| Corcept Therapeutics | $124.98 | 2025 | Korlym |
| Dova Pharmaceuticals | $122.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $120.24 | 2022-2025 | |
| Novo Nordisk INC | $117.12 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $108.64 | 2024-2025 | Vafseo |
| Medtronic Vascular, INC. | $106.23 | 2019 | |
| Baxter Healthcare | $86.34 | 2019 | |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Calliditas Therapeutics US INC. | $22.51 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.22 | 2022 | |
| Cycle Pharmaceuticals INC | $13.93 | 2025 | Venxxiva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Devulapally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.